Search - tctmd.com

Displaying 281 - 300 of 473

Sort: Relevancy | Date

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

Financial Strain Ups Risk of Death After Acute MI in the Elderly

L.A. McKeown

February 25, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Conference News THT 2022

Cardiogenic Shock’s Origins, Progression Tightly Tied to Mortality

Caitlin E. Cox

February 07, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Opinion CV Team Dispatch

February 2022 News Roundup

L.A. McKeown

February 01, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

Todd Neale

January 26, 2022

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Todd Neale

January 21, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Opinion CV Team Dispatch

January 2022 News Roundup

L.A. McKeown

January 01, 2022

News Daily News

Discharge Safe as Early as a Day After Primary PCI for STEMI

L.A. McKeown

December 15, 2021

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Todd Neale

November 17, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

Advertisement

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

Guideline-Directed Therapies Underused in Frail HF Patients

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

March 2022 News Roundup

Financial Strain Ups Risk of Death After Acute MI in the Elderly

FDA Approves Empagliflozin for Treatment of HFpEF

Cardiogenic Shock’s Origins, Progression Tightly Tied to Mortality

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

February 2022 News Roundup

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

January 2022 News Roundup

Discharge Safe as Early as a Day After Primary PCI for STEMI

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 2021 News Roundup

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Canagliflozin Improves Quality of Life in HF Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content